Last reviewed · How we verify
NCT05175404
Use of 18F-PSMA-11 PET for Detection of Lesions in Iodine Refractory Thyroid Cancers
Phase 2 trial testing PET/CT scan F18-PSMA-11 in Thyroid Cancer in 8 participants. Completed in 18 July 2023.
18 July 2023
Quick facts
| Lead sponsor | University Hospital, Ghent |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 8 |
| Start date | 24 January 2022 |
| Primary completion | 18 July 2023 |
| Estimated completion | 18 July 2023 |
| Sites | 1 location across Belgium |
Drugs / interventions tested
- PET/CT scan F18-PSMA-11
Conditions studied
- Thyroid Cancer — all drugs for Thyroid Cancer →
Sponsor
University Hospital, Ghent
Who can join
18 and older, any sex, with Thyroid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Determine the diagnostic value of 18F-PSMA-11 in patients with iodine refractory thyroid cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Potential application of [<sup>18</sup>F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma.
Van den Broeck B, Debacker JM, Bauters W, Creytens D, et al · · 2024 · cited 2× · PMID 39264376 · DOI 10.1186/s13550-024-01148-9
Verify or expand the search:
- PubMed search for NCT05175404
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Thyroid Cancer
Currently open trials in the same condition.
- NCT07428057 — Postoperative Hypocalcemia After Thyroidectomy · recruiting
- NCT07370675 — Active Surveillance for Bethesda IV Thyroid Nodules · NA · recruiting
- NCT07389512 — Pharmaceutical Management in Targeted Radioligand Therapy · recruiting
- NCT07438847 — 177Lu-CTR-FAPI for the Treatment of Thyroid Cancer · Phase 1 · recruiting
- NCT07419932 — Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer · recruiting
Other University Hospital, Ghent trials
Trials by the same sponsor.
- NCT07584486 — Development of a New Simplified Tool to Predict LNPCPs Histology and Assess the Risk of Submucosal Invasive Cancer. The · NA · not yet recruiting
- NCT07327450 — Coaching Doctors and Nurses to Improve Ethical Decision-making in Team · NA · not yet recruiting
- NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
- NCT07387328 — Validation of New sEMG Electrode Placement Guidelines for the Triceps Surae in Post-stroke Individuals. · not yet recruiting
- NCT07237399 — Percutaneous Thermo-ablation for the Treatment of Prostate Cancer Oligometastatasis (TA-P-OLIM) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05175404 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Ghent
- Last refreshed: 4 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05175404.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing